BRISBANE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of an abstract on TPST-1495, a EP2/EP4 prostaglandin receptor dual antagonist, for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL.
Presentation details:
Title: A Phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors
Session Title: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology
Session Date and Time: Saturday, June 3, 2023; 8:00 a.m. – 11:00 a.m. ET
Abstract Number: 3107
The abstract will be released on Thursday, May 25, 2023 at 5:00 p.m. ET on meetings.asco.org.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company has a diverse portfolio of novel programs ranging from early research to investigation in a randomized global study in first-line cancer patients. The company’s two novel clinical programs TPST-1120 and TPST-1495, target of PPARα and EP2/EP4, respectively, are advancing through trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
Aljanae Reynolds
Wheelhouse Life Science Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
1 If approved by the FDA
| Last Trade: | US$1.00 |
| Daily Change: | 0.05 5.27 |
| Daily Volume: | 6,996,209 |
| Market Cap: | US$43.420M |
November 12, 2024 September 05, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
